Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CBFO

General Counsel, Secretary

Chief Operating Officer

President and CMO

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epil...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-18	Premium	bought	Premium	Premium	Premium	CEO
2024-02-22	Premium	acquired	Premium	Premium	Premium	CBFO
2024-02-22	Premium	acquired	Premium	Premium	Premium	General Counsel, Secretary
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2023-12-04	Premium	gifted	Premium	Premium	Premium	CEO
2022-09-12	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2022-07-01	Premium	sold	Premium	Premium	Premium	-
2022-07-01	Premium	acquired	Premium	Premium	Premium	-
2021-07-14	Premium	sold	Premium	Premium	Premium	President and CMO
2021-07-14	Premium	acquired	Premium	Premium	Premium	President and CMO
2020-08-28	Premium	bought	Premium	Premium	Premium	CEO
2019-10-08	Premium	bought	Premium	Premium	Premium	CEO
2019-10-08	Premium	bought	Premium	Premium	Premium	-
2019-09-20	Premium	gifted	Premium	Premium	Premium	CEO
2019-02-26	Premium	bought	Premium	Premium	Premium	-
2019-02-22	Premium	bought	Premium	Premium	Premium	CEO

OVID - Ovid therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for OVID